Paul Friedman’s Madrigal Trade: Buying Low, Selling High – A Signal for Long‑Term Upside?
Discover how Paul Friedman’s January 9 trade on Madrigal Pharmaceuticals reflects a balanced long‑term conviction amid short‑term profit‑taking, and why the company’s pipeline and pricing strategy could drive future gains.
- Madrigal Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read